Regeneron Pharmaceuticals on Tuesday announced that a phase 3 trial still in progress of an antibody cocktail has shown a 100 percent prevention of symptomatic COVID-19 infections. Interim results also show approximately 50 percent lower overall rates of infection across all patients. For infections that did take place, peak virus levels were decreased and they had a short duration of viral shedding. None of the individuals who received the cocktail had high viral loads, compared to 62 percent of the infected who were treated with a placebo. “These data using REGEN-COV as a passive vaccine suggest that it may both reduce transmission of the virus as well as reduce viral and disease burden in those who still get infected,” George Yancopoulos, president and chief scientific officer at Regeneron, said in a statement. “Even with the emerging availability of active vaccines, we continue to see hundreds of thousands of people infected …